Table 1.

Study Participant Demographics

Age of recipient, years, median (25%Q, 75%Q)	50 (40, 58)
Race/ethnicity, n (%)
Black or African American	4 (11)
Hispanic or Latino	7 (18)
White or Caucasian	25 (66)
Unidentified	2 (5)
Female sex, n (%)	32 (84)
Previous renal transplant, n (%)	9 (24)
Presence of 2nd organ transplant, n (%)	13 (34)
Neurogenic bladder, n (%)	2 (5)
Primary etiology of end stage renal disease, n (%)
Diabetic nephropathy	18 (47)
Hypertensive nephrosclerosis	3 (8)
Graft failure	4 (11)
Nonalcoholic steatohepatitis	2 (5)
Systemic Lupus Erythematosus	2 (5)
Chronic glomerulonephritis	2 (5)
Other	7 (18)
GFR pre-methenamine
>60 ml/min/1.73m2, n (%)	11 (29)
<60 ml/min/1.73m2, n (%)	27 (71)
<60 ml/min/1.73m2, median ml/min (minimum ml/min)	45 (21)
GFR post-methenamine
>60 ml/min/1.73m2, n (%)	12 (32)
<60 ml/min/1.73m2, n (%)	26 (68)
<60 ml/min/1.73m2, median ml/min (minimum ml/min)	41 (17)
Follow-up days pre-methenamine
Total for all patients, thousand days	12.1
Individual patients, median (25%Q, 75%Q)	365 (299, 365)
Follow-up days post-methenamine
Total for all patients, thousand days	9.8
Individual patients, median (25%Q, 75%Q)	314 (105, 365)
Days from transplant to methenamine start, median (25%Q, 75%Q)	1192 (300, 2433)
Total days of methenamine treatment, median (25%Q, 75%Q)	314 (105, 566)
Immunosuppressive regimen, n (%)
Mycophenolic acid	35 (92)
Tacrolimus	26 (68)
Sirolimus	4 (11)
Prednisone	9 (24)
Azathioprine	2 (5)
Cyclosporine	3 (8)